Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089765 | 0.79 | MEN1 (0.70) | METMEN1KMT2A | |
| SCHEMBL1151415 | 0.79 | MET (0.70) | METMEN1KMT2ATP53 | |
| SCHEMBL1303077 | 0.74 | MET (0.65) | METMEN1KMT2AHDAC1 | |
| SCHEMBL2466743 | 0.74 | MET (0.65) | METMEN1KMT2AHDAC1 | |
| SCHEMBL1952616 | 0.74 | MET (0.65) | METMEN1KMT2AHDAC1 | |
| SCHEMBL13561689 | 0.74 | MET (0.74) | METMEN1KMT2A | |
| SCHEMBL2464399 | 0.73 | MET (0.52) | METMEN1KMT2ATP53 | |
| SCHEMBL17850432 | 0.73 | MET (0.54) | METMEN1KMT2ATP53 | |
| SCHEMBL3101784 | 0.73 | MET (0.81) | METMEN1KMT2A | |
| SCHEMBL3078895 | 0.73 | MET (0.77) | METMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604036-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| EP-2280962-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2280962-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2280962-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009129905-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129905-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, BRAF | MET 1/4885MEN1 198/4885KMT2A 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.